• silvia.riondino@unicamillus.org

Silvia Riondino

Medical Oncology - MED/06


Professor Riondino graduated in Medicine and Surgery (1991), obtained the Residency in Clinical Pathology (1996), a PhD in Experimental Medicine (2001) and a Post-PhD (2003), at the University of Rome “La Sapienza”.

She has been selected within the Italian selection process (ASN) as Associate Professor for the following subject fields:

– 06/A2 General and Clinical Pathology

– 05/E3 Clinical Biochemistry and Molecular Biology

– 06/N1 Science of Health Professions and Applied Medical Technologies

She is currently a type A Researcher (MED/06) at the University of Tor Vergata, Department of Systems Medicine, assigned to the Medical Oncology Unit.

From 1985 to 2008 she joined the Laboratory of Platelet Pathophysiology of the Department of Experimental Medicine and  Pathology of the University of Rome “La Sapienza”, where she carried out independent research projects.

From 2008 to 2013 she has been the referent of the hematology section of the Department of Laboratory Medicine and Advanced Biotechnologies, of the IRCCS San Raffaele Pisana, Rome.
From 2013 to 2021 she has been an independent researcher for the Research Center of the IRCCS San Raffaele Pisana, Rome, and cooperates with the Multidisciplinary Interinstitutional Biobank (BioBIM).
She is also consultant for the Clinical Trial Unit of the Medical Oncology Operative Unit at the University Hospital “Tor Vergata” of Rome and Contract Professor at the Specialization School in Medical Oncology, where she holds the “Clinical Trial design: the science of Biobanking” course.
Since 2018 she is Teaching Assistant in Oncology at the University of Rome Tor Vergata, for the Degrees in Physiotherapy and Biomedical Laboratory Techniques.

Since 2019 she is Contract Professor of Oncology at the Catholic University “Our Lady of Good Counsel” in Tirane and at UniCamillus International University of Health and Medical Sciences in Rome.

Her main fields of interest, have been the study of:  1) biochemical pathways of platelet pathology and physiology; 2) pathophysiological mechanisms responsible for the thrombophilia state associated with chronic degenerative diseases (chronic obstructive pulmonary disease, cardiovascular diseases), with cardiovascular risk factors (diabetes, hypercholesterolemia, hyperhomocysteinemia, obesity) and certain neoplastic conditions such as breast, colorectal tract and lung cancer; 3) mechanisms involved in the pathogenesis of many chronic disabling diseases, with particular attention to the interactions between inflammation, angiogenesis and hemostasis, to identify biomarkers, “emerging” risk factors and possible determinants of outcome in patients with chronic disabling diseases both in primary prevention, and during the therapeutic/rehabilitation phases of such patients; 4) “quality criteria” to be applied to biological samples for the Biological Bank BioBIM (IRCCS San Raffaele) and PTV-Bio.Ca.Re (University Hospital “Tor Vergata”) projects.
The scientific activity described above has resulted, so far (January 2022), in the publication of 91 full papers in national and international journals, (H-index 26), chapters in books and Abstracts in national and international congresses.